Special Issue

Diagnosis and Therapies of Rheumatoid Arthritis

Message from the Guest Editor

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects 1.5 million Americans and can lead to complete joint destruction and sever disability if left untreated. To date, there is no cure for RA, and up to 40% of RA patients do not respond to standard therapies. including anti-TNF- \boxtimes . Therefore, there is an immediate need for novel diagnostics, therapeutic targets, and therapeutics for the effective diagnosis and management of RA. In this Special Issue, we aim to publish a wide range of manuscripts that investigate RA disease development, pathogenesis, diagnosis/diagnostic tools, evaluation of novel host cell proteins as potential drug targets, and studies that report novel antibodies or small molecules as potential RA therapeutics.

Guest Editor

Dr. Hatem A. Elshabrawy

Department of Biochemistry, Cell Biology & Genetics at the College of Osteopathic Medicine, Sam Houston State University, Huntsville, TX, USA

Deadline for manuscript submissions

closed (1 September 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/81656

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

